Ceftobiprole medocaril

Ceftobiprole medocaril is a broad-spectrum 5th-generation cephalosporin with activity against Gram-positives such as methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae, and against Gram-negatives such as Pseudomonas aeruginosa. The recommended dose is 500 m...

Descripción completa

Detalles Bibliográficos
Autores principales: Méndez, Raúl, Latorre, Ana, González-Jiménez, Paula
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedad Española de Quimioterapia 2022
Materias:
New Antimicrobial Alternatives in the Treatment of Pneumonia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9106187/
https://www.ncbi.nlm.nih.gov/pubmed/35488820
http://dx.doi.org/10.37201/req/s01.05.2022
_version_ 1784708223211667456
author Méndez, Raúl
Latorre, Ana
González-Jiménez, Paula
author_facet Méndez, Raúl
Latorre, Ana
González-Jiménez, Paula
author_sort Méndez, Raúl
collection PubMed
description Ceftobiprole medocaril is a broad-spectrum 5th-generation cephalosporin with activity against Gram-positives such as methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae, and against Gram-negatives such as Pseudomonas aeruginosa. The recommended dose is 500 mg every 8 h in 2-hour infusions. Various clinical trials have demonstrated its usefulness in the treatment of community-acquired pneumonia and nosocomial pneumonia, with the exception of ventilator-associated pneumonia. In summary, it is a very useful antibiotic for the treatment of pneumonia.
format Online
Article
Text
id pubmed-9106187
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Sociedad Española de Quimioterapia
record_format MEDLINE/PubMed
spelling pubmed-91061872022-05-27 Ceftobiprole medocaril Méndez, Raúl Latorre, Ana González-Jiménez, Paula Rev Esp Quimioter New Antimicrobial Alternatives in the Treatment of Pneumonia Ceftobiprole medocaril is a broad-spectrum 5th-generation cephalosporin with activity against Gram-positives such as methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae, and against Gram-negatives such as Pseudomonas aeruginosa. The recommended dose is 500 mg every 8 h in 2-hour infusions. Various clinical trials have demonstrated its usefulness in the treatment of community-acquired pneumonia and nosocomial pneumonia, with the exception of ventilator-associated pneumonia. In summary, it is a very useful antibiotic for the treatment of pneumonia. Sociedad Española de Quimioterapia 2022-04-22 2022 /pmc/articles/PMC9106187/ /pubmed/35488820 http://dx.doi.org/10.37201/req/s01.05.2022 Text en © The Author 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).
spellingShingle New Antimicrobial Alternatives in the Treatment of Pneumonia
Méndez, Raúl
Latorre, Ana
González-Jiménez, Paula
Ceftobiprole medocaril
title Ceftobiprole medocaril
title_full Ceftobiprole medocaril
title_fullStr Ceftobiprole medocaril
title_full_unstemmed Ceftobiprole medocaril
title_short Ceftobiprole medocaril
title_sort ceftobiprole medocaril
topic New Antimicrobial Alternatives in the Treatment of Pneumonia
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9106187/
https://www.ncbi.nlm.nih.gov/pubmed/35488820
http://dx.doi.org/10.37201/req/s01.05.2022
work_keys_str_mv AT mendezraul ceftobiprolemedocaril
AT latorreana ceftobiprolemedocaril
AT gonzalezjimenezpaula ceftobiprolemedocaril

Ejemplares similares